{"id":100856,"date":"2015-03-12T09:02:34","date_gmt":"2015-03-12T13:02:34","guid":{"rendered":"https:\/\/today.uconn.edu\/?p=100856"},"modified":"2015-03-23T09:27:08","modified_gmt":"2015-03-23T13:27:08","slug":"diabetes-drug-shown-not-to-increase-heart-failure-risk","status":"publish","type":"post","link":"https:\/\/today.uconn.edu\/2015\/03\/diabetes-drug-shown-not-to-increase-heart-failure-risk\/","title":{"rendered":"Diabetes Drug Shown Not to Increase Heart Failure Risk"},"content":{"rendered":"
\"A<\/a>
A new study published in the medical journal The Lancet concludes that the diabetes drug Alogliptin does not carry significant increased risk for heart disease. (Shutterstock Photo)<\/figcaption><\/figure>\n

People with the most common form of diabetes can take the new drug Alogliptin without concern for an increased risk of heart failure or cardiovascular disease, according to research by a UConn cardiologist just published in the British medical journal, The Lancet<\/em><\/a>.<\/p>\n

Dr. William White<\/a>, professor of medicine and chief of the Calhoun Cardiology Center<\/a> Division of Hypertension and Clinical Pharmacology at UConn Health, analyzed data from a global clinical trial called EXAMINE<\/a>. Regulatory agencies require a comprehensive\u00a0evaluation of the cardiovascular safety profile of new diabetic therapies.<\/p>\n

\u201cThis new analysis shows that Alogliptin was safe in patients with Type 2 diabetes who we considered at high cardiovascular risk because they had had an acute coronary syndrome before entering the trial,\u201d says White.<\/p>\n

Even in patients who had a history of heart failure\u00a0\u2013 28 percent of participants\u00a0\u2013 there was no increase in hospitalization.<\/p>\n

\"Dr.<\/a>
Dr. William White is senior author of the study, which is based on a global clinical trial of the diabetes drug. (Janine Gelineau\/UConn Health)<\/figcaption><\/figure>\n

The information is significant because of the prevalence of heart disease morbidity and mortality in patients with Type 2 diabetes. According to the World Health Organization, heart disease is responsible for between 50 percent and 80 percent of deaths among diabetics.<\/p>\n

Also, the findings contradict a previous clinical trial of another diabetes medication in the same drug class that showed a modest increase in heart failure risk, leading to a closer scrutiny of Alogliptin\u00a0\u2013 an orally administered anti-diabetic drug in the DPP-4 inhibitor class\u00a0\u2013 in the medical community.<\/p>\n

EXAMINE is an acronym for \u201cExamination of Cardiovascular Outcomes: Alogliptin vs. Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome.\u201d The study included nearly 5,400 diabetics in 49 countries, all of whom were within 90 days of hospitalization for either a heart attack or chest pain related to coronary heart disease. The trial was funded by Japanese pharmaceutical company Takeda, which makes Alogliptin.<\/p>\n

Follow UConn Health<\/a> on Facebook<\/a>, Twitter<\/a>, YouTube<\/a>, and SoundCloud<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

The study, published in The Lancet, is based on data from a global clinical trial led by a UConn Health physician-researcher.<\/p>\n","protected":false},"author":111,"featured_media":100955,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_crdt_document":"","wds_primary_category":0,"wds_primary_series":0,"wds_primary_attribution":0,"footnotes":""},"categories":[2076,179,1],"tags":[],"magazine-issues":[],"coauthors":[57,2010],"class_list":["post-100856","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research","category-uconn-health","category-uncategorized"],"pp_statuses_selecting_workflow":false,"pp_workflow_action":"current","pp_status_selection":"publish","acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-10 23:10:44","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/posts\/100856","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/users\/111"}],"replies":[{"embeddable":true,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/comments?post=100856"}],"version-history":[{"count":5,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/posts\/100856\/revisions"}],"predecessor-version":[{"id":101016,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/posts\/100856\/revisions\/101016"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/media\/100955"}],"wp:attachment":[{"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/media?parent=100856"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/categories?post=100856"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/tags?post=100856"},{"taxonomy":"magazine-issue","embeddable":true,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/magazine-issues?post=100856"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/coauthors?post=100856"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}